The company has announced that it will seek regulatory approval for the third dose of the Pfizer-BioNTech Covid-19 vaccine. Based on the interim clinical trial data, it has been shown that taking a third dose of Pfizer can increase the antibody level by five to 10 times.
On Friday morning, the company reported that a third dose was needed to make the Pfizer-BioNTech Covid-19 vaccine ‘Comirnaty’ more effective against the coronavirus and its variants.
According to ongoing interim trial data, the third dose of the Pfizer vaccine is expected to provide better protection against the Beta variant first identified in South Africa and the delta variants found in India.
The company said a third dose would be needed within six to 12 months of being vaccinated.